The clinical support is robust
The JAMA Internal Medicine meta-analysis of 76 randomized trials quantified the class-wide risk: Cholelithiasis: relative risk 1.27 across all GLP-1 RAs Cholecystitis: relative risk 1.36 Biliary disease composite: relative risk 1.55 Higher doses carried higher risk than lower doses Longer treatment duration carried higher risk than shorter duration For high-risk populations, particularly older women, close monitoring for cholecystitis and cholelithiasis during GLP-1 therapy is recommended
Conjunctivitis (Pink Eye): Defined as inflammation or infection of the conjunctiva, the clear tissue covering the white part of the eye and the inside of the eyelids
DGL (deglycyrrhizinated licorice): Chewable tablets taken before meals increase mucus production that protects the stomach and esophageal lining
Once daily oral semaglutide tablets are taken once a day, preferably in the morning, at least 30 minutes before eating or consuming other medications
In the treatment of diabetes mellitus, its dual actions help lower high blood sugar levels and manage blood pressure
